Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures ... with backup from RiverVest Venture Partners, Red Tree Venture Capital, abrdn, Ysios Capital ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox ...

Stocks plummeted after a fake "verified" Eli Lilly account announced that insulin ... The Twitter name and logo were iconic. The blue bird? Instantly recognizable. So naturally, Musk decided ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Teladoc and LifeMD are partnering with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients. The two telehealth companies said Thursday they’re working ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 25 trades. If we consider the specifics of each ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,100.00. The company’s shares closed yesterday at $911.06.